Invivo Sciences, LLC

Madison, WI 53719

SBIR Award Summary

Total Number of Awards 16
Total Value of Awards $7.55MM
First Award Date 06/01/04
Most Recent Award Date 06/01/17

Key Personnel

Last Name Name Awards Contact
Elson Elliot L. Elson 1
Rufanova Victoriya Aleksandrovna Rufanova 2
Lam Vy Lam 1
Wakatsuki Tetsuro Wakatsuki 12

16 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-052
Budget: 06/01/17 - 04/30/18

Project Summary/Abstract Cardiovascular drugs are primarily prescribed to older people (>65 years of age) since the prevalence of chronic heart failure and fibrillation increases with age. The incidence of other diseases, including cancer and neurological disorders, increases with age, too. Any medications hold potential risks to cause adverse e...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-052
Budget: 08/15/16 - 04/30/17

Project Summary/AbstractCardiovascular drugs are primarily prescribed to older people (>65 years of age) since theprevalence of chronic heart failure and fibrillation increases with age. The incidence of otherdiseases, including cancer and neurological disorders, increases with age, too. Any medicationshold potential risks to cause adverse event...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-322
Budget: 08/01/16 - 05/31/17

? DESCRIPTION (provided by applicant): We propose to demonstrate the strength of combining our engineered tissue-based drug screening approach and a systematically organized mixture-based chemical library. This approach could become an ultimate tool to develop treatments for complex diseases, such as cardiac fibrosis, without known drug target...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-052
Budget: 06/01/16 - 05/31/17

? DESCRIPTION (provided by applicant): We propose to demonstrate the strength of combining our engineered tissue-based drug screening approach and a systematically organized mixture-based chemical library. This approach could become an ultimate tool to develop treatments for complex diseases, such as cardiac fibrosis, without known drug target...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-052
Budget: 09/30/15 - 05/31/16

DESCRIPTION (provided by applicant): We propose to demonstrate the strength of combining our engineered tissue-based drug screening approach and a systematically organized mixture-based chemical library. This approach could become an ultimate tool to develop treatments for complex diseases, such as cardiac fibrosis, without known drug targets in...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-335
Budget: 09/01/15 - 08/31/16

DESCRIPTION (provided by applicant): Cardiomyopathy has various forms including hypertrophic cardiomyopathy (HCM), 1 in 500 prevalence, could cause sudden cardiac death in athletes, Dilated Cardiomyopathy (DCM), 1 in 5000 prevalence, results in an enlarge left ventricle, Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C), 1 in 10...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-335
Budget: 09/15/14 - 08/31/15

DESCRIPTION (provided by applicant): Cardiomyopathy has various forms including hypertrophic cardiomyopathy (HCM), 1 in 500 prevalence, could cause sudden cardiac death in athletes, Dilated Cardiomyopathy (DCM), 1 in 5000 prevalence, results in an enlarge left ventricle, Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C), 1 in 10...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 09/01/13 - 08/31/14

DESCRIPTION (provided by applicant): Current NIGMS-SBIR funding supported InvivoSciences LLC's (IVS) launch of several product lines in 2010. IVS generated revenues from the sales of three-dimensional (3D) cell culture tools (MC-8TM and IVS InsertsTM) that can grow various hydrogel tissues without any support layers. The culture tools enable Pal...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 09/01/13 - 08/31/15

DESCRIPTION (provided by applicant): Current NIGMS-SBIR funding supported InvivoSciences LLC's (IVS) launch of several product lines in 2010. IVS generated revenues from the sales of three-dimensional (3D) cell culture tools (MC-8TM and IVS InsertsTM) that can grow various hydrogel tissues without any support layers. The culture tools enable Pal...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 01/01/13 - 08/31/13

DESCRIPTION (provided by applicant): Heart disease frequently leads to cardiac fibrosis. In almost all cases of chronic heart disease, the myocardium exhibits fibrosis developed by activated cardiac fibroblasts. These fibroblasts are quiescent in the healthy heart. Interstitial fibrosis due to extracellular matrix deposition by fibroblasts incre...

Load More